Mathai Mammen makes an abrupt exit as head of the big R&D group at J&J
In an after-the-bell shocker, J&J announced Monday evening that Mathai Mammen has abruptly exited J&J as head of its top-10 R&D group.
Recruited from Merck five years ago, where the soft-spoken Mammen was being groomed as the successor to Roger Perlmutter, he had been one of the top-paid R&D chiefs in biopharma. His group spent $12 billion last year on drug development, putting it in the top 5 in the industry.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.